Microencapsulated Mammalian Cells for Simultaneous Production of VEGF₁₆₅b and IFNα

Reference

• Orive, G., Hernandez, R.M., Gascon, A.R., Calafiore, R., Chang, T.M., de Vos, P., Hortelano, G., Hunkeler, D., Lacik, I., Shapiro, A.M., and Pedraz, J.L. (2003). Cell encapsulation: promise and progress. Nat. Med., 9:104–107.
   PubMed Web of Science ®Google Scholar
• Chang T.M, (2000). Artificial cell biotechnology for medical applications. Blood Purif., 18: 91–96.
   PubMed Web of Science ®Google Scholar
• De Vos P., Faas M.M., Strand, B., and Calafiore, R. (2006). Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials, 27: 5603–5617.
   PubMed Web of Science ®Google Scholar
• Lanza R.P, Hayes J.L, andChick W.L, (1996). Encapsulated cell technology. Nat. Biotechnol., 14: 1107–1111.
   PubMed Web of Science ®Google Scholar
• Lahooti, S. and Sefton M.V, (2000). Effect of an immobilization matrix and capsule membrane permeability on the viability of encapsulated HEK cells. Biomaterials, 21: 987–995.
   PubMed Web of Science ®Google Scholar
• Orive, G., Hernandez R.M, Gascon A.R, Igartua, M., Rojas, A., andPedraz J.L, (2001). Microencapsulation of an anti-VE-cadherin antibody secreting 1B5 hybridoma cells. Biotechnol. Bioeng., 76: 285–294.
   PubMed Web of Science ®Google Scholar
• Chang P.L, Van Raamsdonk J.M., Hortelano, G., Barsoum S.C, MacDonald N.C., andStockley T.L, (1999). The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotechnol., 17: 78–83.
   PubMed Web of Science ®Google Scholar
• O'Reilly M.S, Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane W.S, Flynn, E., Birkhead J.R, Olsen B.R, andFolkman, J. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277–285.
   PubMed Web of Science ®Google Scholar
• Noonan D.M, Benelli, R., andAlbini, A. (2007). Angiogenesis and cancer prevention: A vision. Recent Results Cancer Res., 174: 219–224.
   PubMedGoogle Scholar
• Folkman, J. (2004). Endogenous angiogenesis inhibitors. APMIS, 112: 496–507.
   PubMed Web of Science ®Google Scholar
• Folkman, J. (2006). Angiogenesis. Annu. Rev. Med., 57: 1–18.
   PubMed Web of Science ®Google Scholar
• Verheul H.M, Voest E.E, and Schlingemann R.O, (2004). Are tumours angiogenesis-dependent? J. Pathol., 202: 5–13.
   PubMed Web of Science ®Google Scholar
• Lamalice, L., Le Boeuf, F., andHuot, J. (2007). Endothelial cell migration during angiogenesis. Circ. Res., 100: 782–794.
   PubMed Web of Science ®Google Scholar
• Bates D.O, Cui T.G, Doughty J.M, Winkler, M., Sugiono, M., Shields J.D, Peat, D., Gillatt, D., andHarper S.J, (2002). VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res., 62: 4123–4131.
   PubMed Web of Science ®Google Scholar
• Bates D.O, andHarper S.J, (2005). Therapeutic potential of inhibitory VEGF splice variants. Future. Oncol., 1: 467–473.
   PubMedGoogle Scholar
• Konopatskaya, O., Churchill A.J, Harper S.J, Bates D.O, andGardiner T.A, (2006). VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis., 12: 626–632.
   PubMed Web of Science ®Google Scholar
• Woolard, J., Wang W.Y, Bevan H.S., Qiu, Y., Morbidelli, L., Pritchard-Jones R.O, Cui T.G, Sugiono, M., Waine, E., Perrin, R., Foster, R., Digby-Bell, J., Shields J.D, Whittles C.E, Mushens R.E, Gillatt D.A., Ziche, M., Harper S.J., andBates D.O, (2004). VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res., 64: 7822–7835.
   PubMed Web of Science ®Google Scholar
• Sidky, Y. A. andBorden E.C, (1987). Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155–5161.
   PubMed Web of Science ®Google Scholar
• Rosewicz, S., Detjen, K., Scholz, A., andvon Marschall, Z. (2004). Interferon-alpha: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology, 80 Suppl 1: 85–93.
   PubMedGoogle Scholar
• Streck C.J, Ng C.Y., Zhang, Y., Zhou, J., Nathwani A.C, andDavidoff A.M, (2005). Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett., 228: 163–170.
   PubMed Web of Science ®Google Scholar
• Peirone, M., Ross C.J, Hortelano, G., Brash J.L, andChang, P. L. (1998). Encapsulation of various recombinant mammalian cell types in different alginate microcapsules. J. Biomed. Mater. Res., 42: 587–596.
   PubMed Web of Science ®Google Scholar
• Ouyang, W., Chen, H., Jones M.L, Metz, T., Haque, T., Martoni, C., andPrakash, S. (2004). Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: Design, preparation, and in-vitro characterization. J. Pharm. Pharm. Sci., 7: 315–324.
   PubMed Web of Science ®Google Scholar
• Bunger C.M, Jahnke, A., Stange, J., De Vos, P., andHopt U.T, (2002). MTS colorimetric assay in combination with a live-dead assay for testing encapsulated L929 fibroblasts in alginate poly-L-lysine microcapsules in vitro. Artif. Organs, 26: 111–116.
   PubMed Web of Science ®Google Scholar
• Stensvaag, V., Furmanek, T., Lonning, K., Terzis A.J, Bjerkvig, R., andVisted, T. (2004). Cryopreservation of alginate-encapsulated recombinant cells for antiangiogenic therapy. Cell Transplant., 13: 35–44.
   PubMed Web of Science ®Google Scholar
• Wen, J., Vargas A.G, Ofosu F.A, andHortelano, G. (2006). Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: Key role of encapsulated cells. J. Gene Med., 8: 362–369.
   PubMed Web of Science ®Google Scholar
• Tai I.T, andSun A.M, (1993). Microencapsulation of recombinant cells: A new delivery system for gene therapy. FASEB J., 7: 1061–1069.
   PubMed Web of Science ®Google Scholar
• Zheng, S., Xiao Z.X, Pan Y.L, Han M.Y, andDong, Q. (2003). Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy. World J. Gastroenterol., 9: 951–955.
   PubMed Web of Science ®Google Scholar
• Hao, S., Su, L., Guo, X., Moyana, T., andXiang, J. (2005). A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells. Exp. Oncol., 27: 56–60.
   PubMed Web of Science ®Google Scholar
• Bjerkvig, R., Read T.A., Vajkoczy, P., Aebischer, P., Pralong, W., Platt, S., Melvik J.E., Hagen, A., andDornish, M. (2003). Cell therapy using encapsulated cells producing endostatin. Acta Neurochir. Suppl, 88: 137–141.
   PubMedGoogle Scholar
• Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried N.T, Dunn I.F., Abe, T., Carroll R.S., andBlack P.M, (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35–39.
   PubMed Web of Science ®Google Scholar
• Read T.A., Farhadi, M., Bjerkvig, R., Olsen B.R, Rokstad A.M, Huszthy P.C., andVajkoczy, P. (2001). Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res., 61: 6830–6837.
   PubMed Web of Science ®Google Scholar
• Read T.A, Sorensen D.R., Mahesparan, R., Enger P.O., Timpl, R., Olsen B.R., Hjelstuen M.H., Haraldseth, O., andBjerkvig, R. (2001). Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol., 19: 29–34.
   PubMed Web of Science ®Google Scholar
• Teng, H., Zhang, Y., Wang, W., Ma, X., andFei, J. (2007). Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells. Acta Biochim. Biophys. Sin.(Shanghai), 39: 278–284.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Wang, W., Zhou, J., Yu, W., Zhang, X., Guo, X., andMa, X. (2007). Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO Cells. Ann. Biomed. Eng., 35: 605–614.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Wang, W., Xie, Y., Yu, W., Teng, H., Liu, X., Zhang, X., Guo, X., Fei, J., andMa, X. (2007). In vivo culture of encapsulated endostatin-secreting Chinese hamster ovary cells for systemic tumor inhibition. Hum. Gene Ther., 18: 474–481.
   PubMed Web of Science ®Google Scholar
• Cirone, P., Bourgeois J.M., Shen, F., andChang P.L, (2004). Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Hum. Gene Ther., 15: 945–959.
   PubMed Web of Science ®Google Scholar
• Cirone, P., Shen, F., andChang, P. L. (2005). A multiprong approach to cancer gene therapy by coencapsulated cells. Cancer Gene Ther., 12: 369–380.
   PubMed Web of Science ®Google Scholar
• Visted, T., Furmanek, T., Sakariassen, P., Foegler W.B., Sim, K., Westphal, H., Bjerkvig, R., andLund-Johansen, M. (2003). Prospects for delivery of recombinant angiostatin by cell-encapsulation therapy. Hum. Gene Ther., 14: 1429–1440.
   PubMed Web of Science ®Google Scholar
• Ferrara, N. (2004). Vascular endothelial growth factor as a target for anticancer therapy. Oncologist., 9 Suppl 1: 2–10.
   PubMed Web of Science ®Google Scholar
• Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology, 69 Suppl 3: 11–16.
   PubMed Web of Science ®Google Scholar
• Frumovitz, M. andSood, A. K. (2007). Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol. Oncol., 104: 768–778.
   PubMed Web of Science ®Google Scholar
• Marler J.J, Rubin J.B., Trede N.S., Connors, S., Grier, H., Upton, J., Mulliken J.B., andFolkman, J. (2002). Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: Report of 2 cases. Pediatrics, 109: E37.
   PubMed Web of Science ®Google Scholar
• Singh R.K., Gutman, M., Bucana C.D., Sanchez, R., Llansa, N., andFidler I.J, (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. U.S.A, 92: 4562–4566.
   PubMed Web of Science ®Google Scholar
• Slaton J.W., Perrotte, P., Inoue, K., Dinney C.P., andFidler, I. J. (1999). Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726–2734.
   PubMed Web of Science ®Google Scholar
• Wang, L., Wu W.Z, Sun H.C, Wu X.F., Qin L.X., Liu Y.K., Liu K.D., andTang Z.Y, (2003). Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg., 7: 587–594.
   PubMed Web of Science ®Google Scholar